Market Cap (In USD)
105.44 Million
Revenue (In USD)
1 Million
Net Income (In USD)
-8.57 Million
Avg. Volume
38.16 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.12-2.55
- PE
- -
- EPS
- -
- Beta Value
- 0.769
- ISIN
- US58468P2065
- CUSIP
- 58468P206
- CIK
- 1226616
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Yuichi Iwaki M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.medicinova.com
- Ipo Date
- 2006-12-08
- Details
- MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
More Stocks
-
JORFFJourdan Resources Inc.
JORFF
-
PM
-
2321Softfront Holdings
2321
-
LEN
-
7709KUBOTEK Corporation
7709
-
IRISIrisity AB (publ)
IRIS
-
7438Kondotec Inc.
7438
-
ULTAUlta Beauty, Inc.
ULTA